抗拓扑异构酶I抗体阳性的局限性皮肤型系统性硬化症患者的表型:来自EUSTAR队列的数据
基于EUSTAR队列中病程≤3年的系统性硬化症患者,比较ATA-lcSSc与ACA-lcSSc、ANA-lcSSc及ATA-dcSSc的主要器官受累风险。ATA-lcSSc的ILD风险高于ACA-lcSSc和ANA-lcSSc、与ATA-dcSSc相似但限制性肺病较少;FVC下降≥10%风险低于ATA-dcSSc,FVC下降≥5%与其他亚型相似。ATA-lcSSc的PMI风险与ANA-lcSSc相似但低于ACA-lcSSc,PH和死亡率在lcSSc亚型间无差异。
要点
- ATA-lcSSc患者ILD风险高于ACA-lcSSc和ANA-lcSSc,与ATA-dcSSc相似但限制性肺病较少。
- ATA-lcSSc的FVC下降≥10%风险低于ATA-dcSSc,FVC下降≥5%与其他亚型相似。
- ATA-lcSSc的PMI风险与ANA-lcSSc相似但低于ACA-lcSSc,PH和死亡率在lcSSc亚型间无差异。
核心结论
- ATA-lcSSc患者ILD风险高,但进展风险低于ATA-dcSSc,支持对该亚组仔细筛查ILD。
研究设计与样本
- 研究纳入EUSTAR队列中入组时病程≤3年的系统性硬化症患者,共1252例,其中ATA-lcSSc 194例(15.5%),随访7.7年(s.d. 3.5)。
- 采用含时间依赖协变量的Cox回归模型,比较ATA-lcSSc与ACA-lcSSc、ANA-lcSSc及ATA-dcSSc的主要器官受累风险。
主要发现
- ATA-lcSSc的ILD风险高于ACA-lcSSc和ANA-lcSSc,与ATA-dcSSc相似,但限制性肺病较少见。
- FVC下降≥10%的风险在ATA-lcSSc中低于ATA-dcSSc(ATA-lcSSc中35%发生)。
- FVC下降≥5%在ATA-lcSSc(58%发生)与其他亚型(包括ATA-dcSSc)之间相似。
- ATA-lcSSc的PMI风险与ANA-lcSSc相似但低于ACA-lcSSc;PH和死亡率风险在lcSSc亚型间无差异。
- 与ATA-dcSSc相比,ATA-lcSSc的任何器官受累、PMI和PH风险更低,死亡率趋于更低。
关键数值与推荐
- ATA-lcSSc占队列15.5%(194/1252),随访7.7年(s.d. 3.5)。
- ATA-lcSSc中FVC下降≥10%发生率为35%,FVC下降≥5%发生率为58%。
临床怎么用
- 作者认为ATA-lcSSc患者ILD风险高,支持对该亚组仔细筛查ILD。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterize patients with positive anti-topoisomerase I (ATA) in lcSSc. METHODS: SSc patients enrolled in the EUSTAR cohort with a disease duration of ≤3 years at database entry were considered. We assessed the risk of major organ involvement in the following groups: ATA-lcSSc vs ACA-lcSSc and vs ANA without specificity (ANA)-lcSSc, and ATA-lcSSc vs ATA-dcSSc. Cox regression models with time-dependent covariates were performed with the following outcomes: new-onset interstitial lung disease (ILD), ILD progression [forced vital capacity (FVC) decline ≥10% and ≥5% vs values at ILD diagnosis), primary myocardial involvement (PMI), pulmonary hypertension (PH), any organ involvement and all-cause mortality. RESULTS: We included 1252 patients [194 ATA-lcSSc (15.5%)], with 7.7 years (s.d. 3.5) of follow-up. ILD risk was higher in ATA-lcSSc vs ACA- and ANA-lcSSc and similar to ATA-dcSSc, although with less frequent restrictive lung disease. The risk of FVC decline ≥10% (35% of ATA-lcSSc) was lower in ATA-lcSSc than in ATA-dcSSc, whereas FVC decline ≥5% occurs similarly between ATA-lcSSc (58% of patients) and other SSc subsets, including ATA-dcSSc. The risk of PMI was similar in ATA-lcSSc and ANA-lcSSc but lower than in ACA-lcSSc; no difference in PH and mortality risk was observed among lcSSc subsets. The risk of any organ involvement, PMI and PH was lower and the mortality tended to be lower in ATA-lcSSc vs ATA-dcSSc. CONCLUSION: ATA-lcSSc patients have a high risk of ILD, albeit with a lower risk of progression compared with ATA-dcSSc, supporting careful screening for ILD in this subgroup.
引用
- Zanatta E, Huscher D, Ortolan A, et al. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology (Oxford). 2022. PMID: 35348643. doi:10.1093/rheumatology/keac188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。